SLC5A2 and heart failure: This has a series of consequences, the most important one being the possible differences in heart failure management between the first datasheet analyzed in the study (2011) and the last (2023), considering the updated versions of the European Society of Cardiology Guidelines (dated from 2021) and the introduction of SGLT2 (sodium-glucose cotransporter-2) inhibitors.